Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways
Sandra B. Haudek, … , Michael D. Schneider, Douglas L. Mann
Sandra B. Haudek, … , Michael D. Schneider, Douglas L. Mann
Published September 4, 2007
Citation Information: J Clin Invest. 2007;117(9):2692-2701. https://doi.org/10.1172/JCI29134.
View: Text | PDF
Research Article Cardiology

TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways

  • Text
  • PDF
Abstract

Transgenic mice with cardiac-restricted overexpression of secretable TNF (MHCsTNF) develop progressive LV wall thinning and dilation accompanied by an increase in cardiomyocyte apoptosis and a progressive loss of cytoprotective Bcl-2. To test whether cardiac-restricted overexpression of Bcl-2 would prevent adverse cardiac remodeling, we crossed MHCsTNF mice with transgenic mice harboring cardiac-restricted overexpression of Bcl-2. Sustained TNF signaling resulted in activation of the intrinsic cell death pathway, leading to increased cytosolic levels of cytochrome c, Smac/Diablo and Omi/HtrA2, and activation of caspases -3 and -9. Cardiac-restricted overexpression of Bcl-2 blunted activation of the intrinsic pathway and prevented LV wall thinning; however, Bcl-2 only partially attenuated cardiomyocyte apoptosis. Subsequent studies showed that c-FLIP was degraded, that caspase-8 was activated, and that Bid was cleaved to t-Bid, suggesting that the extrinsic pathway was activated concurrently in MHCsTNF hearts. As expected, cardiac Bcl-2 overexpression had no effect on extrinsic signaling. Thus, our results suggest that sustained inflammation leads to activation of multiple cell death pathways that contribute to progressive cardiomyocyte apoptosis; hence the extent of such programmed myocyte cell death is a critical determinant of adverse cardiac remodeling.

Authors

Sandra B. Haudek, George E. Taffet, Michael D. Schneider, Douglas L. Mann

×

Figure 5

Myocardial levels of proapoptotic proteins.

Options: View larger image (or click on image) Download as PowerPoint
Myocardial levels of proapoptotic proteins.
(A) The release of mitochond...
(A) The release of mitochondrial Smac/Diablo, Omi/HtrA2, apoptosis-inducing factor (AIF), and Endo G into the cytosol was determined by Western blotting in littermate control, MHCsTNF, MHCsTNF/Bcl-2, and Bcl-2 mouse hearts at 12 weeks of age. (B) Group data for the corresponding protein levels (normalized to GAPDH) are expressed as the ratio of experimental (transgenic) to control (wild-type) mouse groups. *P < 0.05 between MHCsTNF and MHCsTNF/Bcl-2 groups; **P < 0.05 compared with LM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts